160 related articles for article (PubMed ID: 38490077)
21. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
Tonyali S; Yazici S
Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
[TBL] [Abstract][Full Text] [Related]
22. A Review of Twenty Years of Research on the Regulation of Signaling Pathways by Natural Products in Breast Cancer.
Naeem M; Iqbal MO; Khan H; Ahmed MM; Farooq M; Aadil MM; Jamaludin MI; Hazafa A; Tsai WC
Molecules; 2022 May; 27(11):. PubMed ID: 35684353
[TBL] [Abstract][Full Text] [Related]
23. CC Chemokine Ligand 18 Promotes Cell Proliferation and Metastasis of Urothelial Carcinoma via Activating PI3K/mTOR Signaling in Patient with Renal Transplantation.
Bo S; Donghao S; Guangqi K; Ye T
Urol Int; 2018; 101(4):450-458. PubMed ID: 30189425
[TBL] [Abstract][Full Text] [Related]
24. Molecular biology and targeted therapies for urothelial carcinoma.
Seront E; Machiels JP
Cancer Treat Rev; 2015 Apr; 41(4):341-53. PubMed ID: 25828962
[TBL] [Abstract][Full Text] [Related]
25. Comparative mRNA and microRNA expression profiling of three genitourinary cancers reveals common hallmarks and cancer-specific molecular events.
Li X; Chen J; Hu X; Huang Y; Li Z; Zhou L; Tian Z; Ma H; Wu Z; Chen M; Han Z; Peng Z; Zhao X; Liang C; Wang Y; Sun L; Chen J; Zhao J; Jiang B; Yang H; Gui Y; Cai Z; Zhang X
PLoS One; 2011; 6(7):e22570. PubMed ID: 21799901
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory Potential of Dietary Nutraceuticals on Cellular PI3K/Akt Signaling: Implications in Cancer Prevention and Therapy.
Narayanankutty A
Curr Top Med Chem; 2021; 21(20):1816-1831. PubMed ID: 34279200
[TBL] [Abstract][Full Text] [Related]
27. High PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor in urothelial carcinoma.
Zhong Q; Shou J; Ying J; Ling Y; Yu Y; Shen Z; Zhang Y; Li N; Shi Y; Zhou A
Future Oncol; 2021 Aug; 17(22):2893-2905. PubMed ID: 34189951
[TBL] [Abstract][Full Text] [Related]
28. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
29. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
30. Natural Products as PI3K/ Akt Inhibitors: Implications in Preventing Hepatocellular Carcinoma.
Narayanankutty A
Curr Mol Pharmacol; 2021; 14(5):760-769. PubMed ID: 33494690
[TBL] [Abstract][Full Text] [Related]
31. Combined inhibition of BET proteins and class I HDACs synergistically induces apoptosis in urothelial carcinoma cell lines.
Hölscher AS; Schulz WA; Pinkerneil M; Niegisch G; Hoffmann MJ
Clin Epigenetics; 2018; 10():1. PubMed ID: 29312470
[TBL] [Abstract][Full Text] [Related]
32. Induction of apoptosis through inactivation of ROS-dependent PI3K/Akt signaling pathway by platycodin D in human bladder urothelial carcinoma cells.
Park C; Cha HJ; Lee H; Jeong JW; Han M; Song KS; Kim GY; Chang YC; Leem SH; Hyun JW; Kim HS; Hong SH; Choi YH
Gen Physiol Biophys; 2022 Jul; 41(4):263-274. PubMed ID: 35938960
[TBL] [Abstract][Full Text] [Related]
33. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
34. Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers.
Houédé N; Pourquier P
Pharmacol Ther; 2015 Jan; 145():1-18. PubMed ID: 24929024
[TBL] [Abstract][Full Text] [Related]
35. EMP2 induces cytostasis and apoptosis via the TGFβ/SMAD/SP1 axis and recruitment of P2RX7 in urinary bladder urothelial carcinoma.
Li CF; Chan TC; Pan CT; Vejvisithsakul PP; Lai JC; Chen SY; Hsu YW; Shiao MS; Shiue YL
Cell Oncol (Dordr); 2021 Oct; 44(5):1133-1150. PubMed ID: 34339014
[TBL] [Abstract][Full Text] [Related]
36. Cell-Intrinsic Tumorigenic Functions of PPARγ in Bladder Urothelial Carcinoma.
Sanchez DJ; Missiaen R; Skuli N; Steger DJ; Simon MC
Mol Cancer Res; 2021 Apr; 19(4):598-611. PubMed ID: 33431608
[TBL] [Abstract][Full Text] [Related]
37. Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS; Wang K; Khaira D; Ali SM; Fisher HA; Mian B; Nazeer T; Elvin JA; Palma N; Yelensky R; Lipson D; Miller VA; Stephens PJ; Subbiah V; Pal SK
Cancer; 2016 Mar; 122(5):702-11. PubMed ID: 26651075
[TBL] [Abstract][Full Text] [Related]
38. Phosphatidylinositol 3'-kinase, mTOR, and glycogen synthase kinase-3β mediated regulation of p21 in human urothelial carcinoma cells.
Yohn NL; Bingaman CN; DuMont AL; Yoo LI
BMC Urol; 2011 Aug; 11():19. PubMed ID: 21864408
[TBL] [Abstract][Full Text] [Related]
39. Celecoxib Synergistically Enhances MLN4924-Induced Cytotoxicity and EMT Inhibition Via AKT and ERK Pathways in Human Urothelial Carcinoma.
Xiong S; Huang W; Liu X; Chen Q; Ding Y; Huang H; Zhang R; Guo J
Cell Transplant; 2022; 31():9636897221077921. PubMed ID: 35176901
[TBL] [Abstract][Full Text] [Related]
40. ETV5 links the FGFR3 and Hippo signalling pathways in bladder cancer.
di Martino E; Alder O; Hurst CD; Knowles MA
Sci Rep; 2019 Apr; 9(1):5740. PubMed ID: 30952872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
